Main Article Content


E.T. Taylakova

The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Kazakhstan

O.V. Chervyakova

The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Kazakhstan


Vaccination is an effective means of preventing the dissemination of infectious diseases and therefore, improvement of existing prophylactic measured is urgent. Recombinant proteins with antigenic and immunogenic properties have been widely used in recently developed prophylactic preparations. The objective of this study was to generate recombinant proteins of the sheep pox virus for the development of a subunit SPV vaccine, since outbreaks of the infection have been more frequently reported in the republic and threaten the progress of animal husbandry. In this study, the conditions for the expression of the SPV genes sppv-95 and sppv-141 in a bacterial system were optimised. It was shown that recombinant protein expression levels were optimal after incubation at 37°С for 4 h, following induction with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for gene sppv-95, and at 25°С and 0.25 mM IGPT for gene sppv-141. The expression of the target recombinant proteins was confirmed by immunoblotting using serum against polyhistidine. The recombinant proteins were shown to interact in serological tests with antibodies to SPV, thus confirming the retention of their specific antigenic activity following expression in a prokaryotic system. The resulting recombinant proteins will be used in the development of prophylactic preparations.


recombinant protein, cloning, expression, induction, sheep pox virus

Article Details


Sjurin V.N., Samujlenko A.Ja., Solov'ev B.F. i dr. Вирусные болезни животных [Viral diseases of animals]. M., VNITIBP, 1998, pp.128-134.

Levefre P.C. Sheep and goats pox. Ins. Elev.Med.Vet.: Pays trop. Prod.,1983,p.171.

Bakulov I.A., Vlasova T.A., Ternovaja S.F.i dr. Особо опасные болезни животных: Справочник [Particularly dangerous animal diseases]. Pokrov, VNIIVViM, 2002, p. 159.

World Animal Health. Reports on the animal Health Status and Disease Control Methods and List a Disease Outbreaks. Paris, Statistics O.I.E., 1996, p. 4.

Ivanjushhenkov V.N., Kekuh V.T., Koreba O.A. Реактогенныесвойствавирусвакциныпротивоспыовец [Reactogenicity properties virusvaktsiny against sheep pox]. Veterinary Journal, 1990, no. 7, pp. 28-30.

Shhelkunov S.N. Вакцины на основе вирусных антигенов. Противовирусные вакцины: от дженнера до наших дней. Биология [Vaccines based on virus antigens. Antiviral vaccines from Jenner to the present day. Biology]. SorosEducationalJournal,1998, no. 8, pp. 43-50.CROSSREF.

Moss B., Knipe D.M., etc. Poxviridae and their replication. Fields virology, 2nd ed. Raven press. NY, 1990, p. 120.

Kurchenko F.P., Ivanjushhenkov V.N., Ufimcev K.P. i dr. Эффективность сухой культуральной вакцины из штамма НИСХИ против оспы овец [The effectiveness of a dry culture of a vaccine against a strain of sheep pox].Veterinary Journal,1991, no. 10, pp.21-23.

Jadhav K.M., Pandey A.K., Radadia N.S. Field observations on sheep pox tissue culture vaccine. Indian Vet. J., 1989, vol. 66, pp. 908-912.

Glik B., Pasternak Dzh. Молекулярная биотехнология. Принципы и применение [Molecular Biotechnology. Principles and Applications]. M., Mir, 2002, pp. 228-229.

Tajlakova Je.T., Azhibaeva D.T., Chervjakova O.V. i dr.Создание генетических конструкции для экспрессии рекомбинантных белков А4L и B5R вируса оспы овец [Creation of genetic constructs for the expression of recombinant proteins A4L and B5R sheep pox virus]. Recent biological safety problems and prospects: Coll. articles of scientific-practical conference. Gvardeiskiy, 2012, pp. 174-179.

BugBuster® Protein Extraction Reagent //URL search_p/search_gate2/docs/NVG_/714563.20051122.pdf.

Ni-NTA Purification System for purification of polyhistidine-containing recombinant proteins //URL system man.pdf.

Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, vol. 227, pp.680-685.PubMed.

Vannovskij T.Ja.Оспа коз и ее специфическая профилактика: автореф. …докт.вет. наук [Smallpox goats and its specific prevention: the author's abstract of the dissert. of the doct. of veter. sciences].Voronezh, 1966,p. 342.

Breiman A., Smith G.L. The vaccinia virus B5 protein affects the glycosylation, localisation and stability of the A34 protein.J Gen Virol., 2010, vol. 91, pp.1823-27.PubMed.

Berhanu A., Wilson R.L., Kirkwood D.L -Watts et. al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.J. Virol.,2008, vol. 82, pp.3517-3529.PubMed.

Bell E., ShamimА.M., Whitbeck al. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology, 2004, vol. 325, pp. 425-431.CROSSREF.

Roos N., Cyrklaff M., Cudmore al. The use of a novel immunogoldcryoelectron microscopic method to investigate the structure of the intracellular and xtracellular forms of vaccinia virus. EMBO J., 1996, vol. 151, pp. 2343-2355.PubMed.

Yadav M.P., Pandey A.B., Negi B.S. et al. Studies on an inactivated goat pox vaccine. Indian J. Virol., 1986, vol. 2, pp. 202-221.CROSSREF.

Glik B., Pasternak Dzh. Молекулярная биотехнология. Принципы и применение [Molecular Biotechnology. Principles and Applications]. M., Mir, 2002, p. 131.